Hormonal

Dual GIP/GLP-1 receptor agonism (e.g., tirzepatide) produces superior glycemic control and body weight loss compared to selective GLP-1 receptor agonists (e.g., dulaglutide) in type 2 diabetes, likely by enhancing WAT lipid buffering and CNS-mediated appetite suppression.

For individuals with Type 2 Diabetes, dual-acting incretin medications (like tirzepatide) that target both GIP and GLP-1 receptors have shown superior results in lowering blood sugar and reducing body weight compared to older GLP-1-only medications. This is achieved through once-weekly dosing. The mechanism involves not just appetite suppression in the brain, but also improved fat storage capacity in white adipose tissue, which helps manage blood lipids. While gastrointestinal side effects like nausea are common, the dual mechanism may actually help mitigate some of these side effects compared to high-dose GLP-1 monotherapy, allowing for better long-term adherence and efficacy.